NCT00881179View on ClinicalTrials.gov

To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Non-Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

June 30, 2002

Study Completion Date

June 30, 2002

Conditions
Healthy
Interventions
DRUG

Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)

DRUG

Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)

Sponsors

Lead Sponsor

Sandoz
All Listed Sponsors
lead

Sandoz

INDUSTRY

NCT00881179 - To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Non-Fasting Conditions | Biotech Hunter | Biotech Hunter